Characterization and Comprehensive Genome Analysis of Novel Bacteriophage, VB_Kpn_ZCKp20p, with Lytic and Anti-biofilm Potential Against Clinical Multidrug-resistant
Overview
Infectious Diseases
Microbiology
Affiliations
Introduction: The rise of infections by antibiotic-resistant bacterial pathogens is alarming. Among these, is a leading cause of death by hospital-acquired infections, and its multidrug-resistant strains are flagged as a global threat to human health, which necessitates finding novel antibiotics or alternative therapies. One promising therapeutic alternative is the use of virulent bacteriophages, which specifically target bacteria and coevolve with them to overcome potential resistance. Here, we aimed to discover specific bacteriophages with therapeutic potential against multiresistant clinical isolates.
Methods And Results: Out of six bacteriophages that we isolated from urban and medical sewage, phage vB_Kpn_ZCKp20p had the broadest host range and was thus characterized in detail. Transmission electron microscopy suggests vB_Kpn_ZCKp20p to be a tailed phage of the siphoviral morphotype. evaluation indicated a high lytic efficiency (30 min latent period and burst size of ∼100 PFU/cell), and extended stability at temperatures up to 70°C and a wide range of (2-12) pH. Additionally, phage vB_Kpn_ZCKp20p possesses antibiofilm activity that was evaluated by the crystal violet assay and was not cytotoxic to human skin fibroblasts. The whole genome was sequenced and annotated, uncovering one tRNA gene and 33 genes encoding proteins with assigned functions out of 85 predicted genes. Furthermore, comparative genomics and phylogenetic analysis suggest that vB_Kpn_ZCKp20p most likely represents a new species, but belongs to the same genus as phages ZCKP8 and 6691. Comprehensive genomic and bioinformatics analyses substantiate the safety of the phage and its strictly lytic lifestyle.
Conclusion: Phage vB_Kpn_ZCKp20p is a novel phage with potential to be used against biofilm-forming and could be a promising source for antibacterial and antibiofilm products, which will be individually studied experimentally in future studies.
Abdel-Razek M, Nazeih S, Yousef N, Askoura M AMB Express. 2025; 15(1):37.
PMID: 40044971 PMC: 11882492. DOI: 10.1186/s13568-025-01846-0.
Phage vB_KlebPS_265 Active Against Resistant/MDR and Hypermucoid K2 Strains of .
Yakubovskij V, Morozova V, Kozlova Y, Tikunov A, Fedorets V, Zhirakovskaya E Viruses. 2025; 17(1).
PMID: 39861872 PMC: 11769527. DOI: 10.3390/v17010083.
Huang Y, Huang Y, Wu Z, Fan Z, Zheng F, Liu Y Virulence. 2025; 16(1):2450462.
PMID: 39803864 PMC: 11730680. DOI: 10.1080/21505594.2025.2450462.
Amarillas L, Padilla-Lafarga F, Leon Chan R, Padilla J, Lugo-Melchor Y, Lopez Avendano J Viruses. 2024; 16(11).
PMID: 39599826 PMC: 11598880. DOI: 10.3390/v16111711.
Ndiaye I, Debarbieux L, Sow O, Sambe Ba B, Diagne M, Cisse A BMC Microbiol. 2024; 24(1):449.
PMID: 39501140 PMC: 11536776. DOI: 10.1186/s12866-024-03608-7.